Shares of Aastrom bounced higher yesterday as biotech veteran Dominick Colangelo was named the new CEO, taking the reins during a crucial pivotal study of the company's personalized cell therapy.
Percutaneous transluminal angioplasty with nitinol stenting offers promise as a treatment for peripheral artery disease or critical limb ischemia, according to results of a new trial published in Catheterization and Cardiovascular Interventions, a Wiley journal published on behalf of the Society for Cardiovascular Angiography and Interventions.
More than a year after flagging its interest in a B round, Cleveland Clinic-spinout Juventas Therapeutics has put the final pieces together for a $22.2 million raise.
Cook Medical is backing a new clinical study designed to test a new endovascular treatment in as many as 200 patients to address a major complication associated with peripheral artery disease that can lead to leg amputation.
Aastrom Biosciences' ($ASTM) stock was up this morning after the developer announced a $40 million financing deal with Eastern Capital.